Infant Microbiota Restoration With Maternal Microbes (MaMi)

University of Helsinki

Status: Enrolling

Conditions: Microbiota, Cesarean Section, Probiotics, Dysbiosis; Microbiology; Pregnancy; Vaginal Delivery; Gut Dysbiosis; Cesarean Section; Gut -Microbiota; Cesarean Delivery Affecting Newborn; Neonate; Humans; Infant, Newborn; Delivery, Obstetric; Feces; Gastrointestinal Microbiota; Microbiota

Treatments: Dietary Supplement: Probiotic; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT07212361

HUS/617/2025/71

Details and patient eligibility

About

The goal of this clinical trial is to test the ability of different bacterial products in restoring natural gut microbiota in C-section born infants. The main question it aims to answer is:

Do maternally derived strains of bacteria perform better than commercially available probiotic strains in restoring the gut microbiota of C-section born infants? Researchers will compare the gut microbiota of treated infants to that of untreated C-section born infants and untreated vaginally born infants to see if the bacterial treatments cause the microbiota to resemble that of vaginally born infants.

Participants will be given a bacterial product orally once daily for either one or four weeks and be asked to collect faecal, urine and saliva samples.

Full description

The gut microbiota has long-term effects on host health especially in early life. Infants receive maternal faecal microbes during vaginal birth, which is prevented by C-section. C-section is associated with increased risk of many chronic diseases, likely because of the disturbed gut microbiota. We recently showed the effectiveness of a faecal microbiota transplant from the infant's own mother in restoring normal gut microbiota in C-section born infants. However, FMT contains a large diversity of unknown microbes, some of which may pose a risk of dangerous infection. A safe and widely applicable infant microbiota restoration method is urgently needed. In this project, we develop a selective microbiota transplant from mother to infant and test its efficacy and safety in a clinical trial. The work is conducted in the Faculty of Medicine, University of Helsinki.

Enrollment: 100 estimated patients

Sex: All

Ages: Under 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy mother and healthy pregnancy
• Singleton pregnancy,
• Mothers who speak Finnish or Swedish
• Mothers who are planning to breastfeed or give breastmilk by bottle to the infant
• Infants who are expected to be healthy and who will not require BCG vaccination.

Exclusion criteria

• Participants who lives further than a 2-hour drive from Meilahti, Helsinki, Finland
• Mothers who are not planning to breastfeed or feed breastmilk by bottle to the infant
• Mothers who are diagnosed with gestational diabetes, pre-eclampsia or who have been receiving antibiotics during the pregnancy or delivery
• Premature infants born before the pregnancy week 37
• Infants, who are born by urgent cesarean section or emergency cesarean section
• Infants, who receive antibiotics during the first week of life
• Infants, who are diagnosed with a disease, congenital anomaly or who receive less than 9 Apgar points at 5 minutes.
• Infants, who receive BCG-vaccine

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 6 patient groups, including a placebo group

Probiotic

Active Comparator group

Description:

The infants will receive a mixture of probiotic strains currently on the market and with known safety profiles and beneficial effects on infant gut microbiota.

Treatment:

Dietary Supplement: Probiotic

Vaginal delivery

No Intervention group

Maternal bacteria set 1

Experimental group

Description:

The infants will receive a micture of bacteria isolated from a fecal sample of the infants' own mother.

Treatment:

Dietary Supplement: Probiotic

Maternal bacteria set 2

Experimental group

Description:

The infants will receive a mixture of bacterial species with increased diversity isolated from the mother's sample.

Treatment:

Dietary Supplement: Probiotic

Maternal bacteria set 3

Other group

Description:

The infants will receive a mixture of bacterial strains isolated from other infants' and/or mothers' samples to test whether bacteria from an unrelated donor have different effects compared to maternal bacteria. In this group all infants will receive the same standardised mixture of bacterial strains.

Treatment:

Dietary Supplement: Probiotic

Placebo

Placebo Comparator group

Description:

C-section born infants given a placebo treatment.

Treatment:

Other: Placebo